Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

15.34
-0.2400-1.54%
Post-market: 15.340.00000.00%19:35 EDT
Volume:1.19M
Turnover:18.38M
Market Cap:1.21B
PE:7.56
High:15.86
Open:15.58
Low:15.24
Close:15.58
52wk High:16.77
52wk Low:5.70
Shares:78.65M
Float Shares:70.64M
Volume Ratio:0.59
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:5.20
PE(LYR):8.20

Loading ...

PagerDuty Q2 Adjusted Earnings, Revenue Rise; Sets Q3 Guidance

MT Newswires Live
·
Aug 28

Workflow Automation Firm PagerDuty's Q2 Adj EPS Rises

Reuters
·
Aug 28

GUIDANCE: (PD) PagerDuty Expects Fiscal 2027 Revenue Range $491.5M - $496.5M, vs. FactSet Est of $494.2M

MT Newswires Live
·
Aug 28

GUIDANCE: (PD) PagerDuty Expects Fiscal Q3 Adjusted EPS Range $0.34 - $0.36, vs. FactSet Est of $0.34

MT Newswires Live
·
Aug 28

Earnings Flash (PD) PagerDuty Posts Q2 Adjusted EPS $0.32, vs. FactSet Est of $0.31

MT Newswires Live
·
Aug 28

PagerDuty Q2 FY27 Net Income Falls to $4.7 Million; Revenue Rises 0.8% to $124.4 Million

Reuters
·
Aug 28

PagerDuty Q2 Revenue USD 124.436 Million

THOMSON REUTERS
·
Aug 28

PagerDuty Q2 Adjusted EPS USD 0.32

THOMSON REUTERS
·
Aug 28

PagerDuty - Restructuring Charges Expected in Q3 Fy2027; Headcount Reductions Complete by End of Q4 Fy2027 - SEC Filing

THOMSON REUTERS
·
Aug 28

PagerDuty - Announces Headcount Reduction of About 15% - SEC Filing

THOMSON REUTERS
·
Aug 28

PagerDuty - Estimates Non-Recurring Charges of $5.50 Mln-$7.50 Mln for Headcount Reductions - SEC Filing

THOMSON REUTERS
·
Aug 28

PagerDuty Q2 Adj. EPS $0.32 Beats $0.31 Estimate, Sales $124.436M Beat $123.013M Estimate

Benzinga Earnings
·
Aug 28

U.S. Earnings Preview: After Market Close Aug. 27

Dow Jones
·
Aug 28

PagerDuty, Inc. Expected to Post Earnings of 31 Cents a Share - Earnings Preview

Reuters
·
Aug 26

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

GlobeNewswire
·
Aug 25

Annovis to Host Corporate Update Webinar on September 2, 2026

GlobeNewswire
·
Aug 25

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

GlobeNewswire
·
Aug 25

LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase

Stock News
·
Aug 25

Nanjing Leads Biolabs’ PD-L1/4-1BB Cancer Drug Wins Priority Review in China

TIPRANKS
·
Aug 21

Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody

Stock News
·
Aug 21